ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Cheng AC, Currie BJ, 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18: 383–416.
-
3.
Schweizer HP, 2012. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol 7: 1389–1399.
-
4.
Cheng AC, 2010. Melioidosis: advances in diagnosis and treatment. Curr Opin Infect Dis 23: 554–559.
-
5.
Huntington JA, Sakoulas G, Umeh O, Cloutier DJ, Steenbergen JN, Bliss C, Goldstein EJ, 2016. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother 71: 2014–2021.
-
6.
Solomkin J et al. 2015. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60: 1462–1471.
-
7.
FDA, 2014. Prescribing Information—Ceftolozane/Tazobactam. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf. Accessed January 16, 2018.
-
8.
EUCAST, 2017. Addendum on Ceftolozane-Tazobactam Zone Diameter Breakpoints for Pseudomonas aeruginosa. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Addenda/Addendum_June_2017_ceftolozane-tazobactam.pdf. Accessed August 28, 2017.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 457 | 416 | 26 |
| Full Text Views | 565 | 12 | 0 |
| PDF Downloads | 87 | 8 | 0 |
Activity of Ceftolozane–Tazobactam against Burkholderia pseudomallei
Andrew Slack
Andrew Slack
Department of Infectious Disease, Internal Medicine Department, Townsville Hospital, Townsville, Australia;
Search for other papers by Andrew Slack in
Current site
Google Scholar
PubMed
Search for other papers by Andrew Slack in
Current site
Google Scholar
PubMed
Fiona Parsonson
Fiona Parsonson
Pathology Queensland, Townsville Hospital, Townsville, Australia
Search for other papers by Fiona Parsonson in
Current site
Google Scholar
PubMed
Search for other papers by Fiona Parsonson in
Current site
Google Scholar
PubMed
Katie Cronin
Katie Cronin
Pathology Queensland, Townsville Hospital, Townsville, Australia
Search for other papers by Katie Cronin in
Current site
Google Scholar
PubMed
Search for other papers by Katie Cronin in
Current site
Google Scholar
PubMed
Cathy Engler
Cathy Engler
Pathology Queensland, Townsville Hospital, Townsville, Australia
Search for other papers by Cathy Engler in
Current site
Google Scholar
PubMed
Search for other papers by Cathy Engler in
Current site
Google Scholar
PubMed
Robert Norton
Robert Norton
Pathology Queensland, Townsville Hospital, Townsville, Australia
Search for other papers by Robert Norton in
Current site
Google Scholar
PubMed
Search for other papers by Robert Norton in
Current site
Google Scholar
PubMed
We investigated the in vitro activity of a novel fifth-generation cephalosporin–tazobactam combination, ceftolozane–tazobactam against Burkholderia pseudomallei, the etiological agent of melioidosis. Using both disc diffusion and minimum inhibitory concentration (MIC) strip techniques against 56 clinical isolates and an national collection of type cultures (NCTC) strain, the MIC to ceftolozane–tazobactam was found to be between 0.75 and 4 mcg/mL. The MIC50 was found to be 1.5 mcg/mL and MIC90 was 2.0 mcg/mL. This study provides initial evidence of ceftolozane–tazobactam as a novel agent in the management of melioidosis.
Author Notes
Financial support: Financial support in the form of materials was supplied by Merck Sharp & Dohme Pty Ltd (MSD).
Authors’ addresses: Andrew Slack, Department of Infectious Diseases, Townsville Hospital and Health Service, Townsville, Australia, E-mail: at.slack@gmail.com. Fiona Parsonson, Katie Cronin, Cathy Engler, and Robert Norton, Department of Microbiology, Townsville Hospital, Townsville, Australia, E-mails: fiona.parsonson@health.qld.gov.au, katie.cronin@health.qld.gov.au, cathy.engler@health.qld.gov.au, and robert.norton@health.qld.gov.au.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Cheng AC, Currie BJ, 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18: 383–416.
-
3.
Schweizer HP, 2012. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol 7: 1389–1399.
-
4.
Cheng AC, 2010. Melioidosis: advances in diagnosis and treatment. Curr Opin Infect Dis 23: 554–559.
-
5.
Huntington JA, Sakoulas G, Umeh O, Cloutier DJ, Steenbergen JN, Bliss C, Goldstein EJ, 2016. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother 71: 2014–2021.
-
6.
Solomkin J et al. 2015. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60: 1462–1471.
-
7.
FDA, 2014. Prescribing Information—Ceftolozane/Tazobactam. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf. Accessed January 16, 2018.
-
8.
EUCAST, 2017. Addendum on Ceftolozane-Tazobactam Zone Diameter Breakpoints for Pseudomonas aeruginosa. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Addenda/Addendum_June_2017_ceftolozane-tazobactam.pdf. Accessed August 28, 2017.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 457 | 416 | 26 |
| Full Text Views | 565 | 12 | 0 |
| PDF Downloads | 87 | 8 | 0 |